medigraphic.com
Academia Mexicana de Neurología, A.C.

2019, Number 4

<< Back Next >>

Rev Mex Neuroci 2019; 20 (4)

Pharmacogenetics of adverse cutaneous reactions to lamotrigine

Peña-Balderas AM, López-Revilla R

Language: English
References: 26
Page: 200-206
PDF size: 285.17 Kb.


ABSTRACT

Cutaneous adverse drug reactions include maculopapular exanthema, Stevens-Johnson syndrome, and toxic epidermal necrolysis and are a global public health problem associated with the use of antiepileptic drugs (AEDs). Lamotrigine (LTG) stands out among AEDs because it does not cause sedation and does not affect cognition. Cutaneous adverse reactions (cADRs) to LTG occur in patients carrying certain allele variants of the human leukocyte antigen (HLA) system; although infrequent, they are alarming because they put the life at risk and force discontinuation of the treatment. The fear of neurologists to cADRs to LTG decreases its prescription despite its therapeutic advantages. Here, we review the allele variants of the HLA system that have been associated with cADRs to LTG in Mexican mestizos and other ethnic groups; identification of these variants would serve to select the patients that may be treated with LTG.


REFERENCES

  1. Shi YW, Min FL, Zhou D, Qin B, Wang J, Hu FY, et al. HLA-A*24:02 as a common risk factor for antiepileptic drug-induced cutaneous adverse reactions. Neurology. 2017;88:2183-91.

  2. Fisher RS, van Emde Boas W, Blume W, Elger C, Genton P, Lee P, et al. Epileptic seizures and epilepsy: definitions proposed by the international league against epilepsy (ILAE) and the international bureau for epilepsy (IBE). Epilepsia. 2005;46:470-2.

  3. Berg AT, Berkovic SF, Brodie MJ, Buchhalter J, Cross JH, van Emde Boas W, et al. Revised terminology and concepts for organization of seizures and epilepsies: report of the ILAE commission on classification and terminology, 2005-2009. Epilepsia. 2010;51:676-85.

  4. Shorvon SD. The causes of epilepsy: changing concepts of etiology of epilepsy over the past 150 years. Epilepsia. 2011;52:1033-44.

  5. Fricke-Galindo I, Jung-Cook H, LLerena A, López-López M. Pharmacogenetics of adverse reactions to antiepileptic drugs. Neurologia. 2018; 33:165-76.

  6. López M, Dorado P, Monroy N, Alonso ME, Jung-Cook H, Machín E, et al. Pharmacogenetics of the antiepileptic drugs phenytoin and lamotrigine. Drug Metabol Drug Interact. 2011;26:5-12.

  7. Warshavsky A, Eilam A, Gilad R. Lamotrigine as monotherapy in clinical practice: efficacy of various dosages in epilepsy. Brain Behav. 2016; 6:e00419.

  8. Motte J, Trevathan E, Arvidsson JF, Barrera MN, Mullens EL, Manasco P, et al. Lamotrigine for generalized seizures associated with the lennox- gastaut syndrome. Lamictal lennox-gastaut study group. N Engl J Med. 1997;337:1807-12.

  9. Beattie K, Phadke G, Novakovic J. Lamotrigine. Profiles Drug Subst Excip Relat Methodol. 2012;37:245-85.

  10. Goldsmith DR, Wagstaff AJ, Ibbotson T, Perry CM. Lamotrigine: a review of its use in bipolar disorder. Drugs. 2003;63:2029-50.

  11. World Health Organization. International Drug Monitoring: The Role of National Centers. Geneva: World Health Organization; 1972. Available from: http://www.apps.who.int/iris/bitstream/handle/10665/40968/WHO_ TRS_498.pdf?sequence=1&isAllowed=y.

  12. Fricke-Galindo I, Martínez-Juárez IE, Monroy-Jaramillo N, Jung-Cook H, Falfán-Valencia R, Ortega-Vázquez A, et al. HLA-A*02:01:01/- B*35:01:01/-C*04:01:01 haplotype associated with lamotrigine-induced maculopapular exanthema in Mexican mestizo patients. Pharmacogenomics. 2014;15:1881-91.

  13. Kalow W. Pharmacogenetics and pharmacogenomics: origin, status, and the hope for personalized medicine. Pharmacogenomics J. 2006;6:162-5.

  14. Cao H, Wu J, Wang Y, Jiang H, Zhang T, Liu X, et al. An integrated tool to study MHC region: accurate SNV detection and HLA genes typing in human MHC region using targeted high-throughput sequencing. PLoS One. 2013;8:e69388.

  15. Varney MD, Castley AS, Haimila K, Saavalainen P. Methods for diagnostic HLA typing in disease association and drug hypersensitivity. Methods Mol Biol, 2012;882:27-46.

  16. Gough SC, Simmonds MJ. The HLA region and autoimmune disease: associations and mechanisms of action. Curr Genomics. 2007;8:453-65.

  17. Shirzadi M, Thorstensen K, Helde G, Moen T, Brodtkorb E. Do HLA-A markers predict skin-reactions from aromatic antiepileptic drugs in a norwegian population? A case control study. Epilepsy Res. 2015;118:5-9.

  18. Erlich H. HLA DNA typing: past, present, and future. Tissue Antigens 2012;80:1-1.

  19. Oliveira GC, Ambrosio-Albuquerque EP, Visentainer JE, Oliveira GC, Ambrosio-Albuquerque EP, Visentainer JE. Application of PCR-SSP method for HLA-B*27 identification as an auxiliary tool for diagnosis of ankylosing spondylitis. J Bras Patol Med Lab. 2016;52:217-22.

  20. Fricke-Galindo I, LLerena A, López-López M. An update on HLA alleles associated with adverse drug reactions. Drug Metab Pers Ther. 2017;32:73-87.

  21. Moon J, Park HK, Chu K, Sunwoo JS, Byun JI, Lim JA, et al. The HLA-A*2402/Cw*0102 haplotype is associated with lamotrigine-induced maculopapular eruption in the korean population. Epilepsia. 2015; 56:e161-7.

  22. Li LJ, Hu FY, Wu XT, An DM, Yan B, Zhou D, et al. Predictive markers for carbamazepine and lamotrigine-induced maculopapular exanthema in han Chinese. Epilepsy Res. 2013;106:296-300.

  23. Kazeem GR, Cox C, Aponte J, Messenheimer J, Brazell C, Nelsen AC, et al. High-resolution HLA genotyping and severe cutaneous adverse reactions in lamotrigine-treated patients. Pharmacogenet Genomics. 2009;19:661-5.

  24. Park HJ, Kim SR, Leem DW, Gearing M. Clinical features of and genetic predisposition to drug-induced stevens-johnson syndrome and toxic epidermal necrolysis in a single Korean tertiary institution patients-investigating the relation between the HLA -B*4403 allele and lamotrigine. Eur J Clin Pharmacol. 2015;71:35-41.

  25. Ramírez E, Bellón T, Tong HY, Borobia AM, de Abajo FJ, Lerma V, et al. Significant HLA class I type associations with aromatic antiepileptic drug (AED)-induced SJS/TEN are different from those found for the same AED-induced DRESS in the spanish population. Pharmacol Res. 2017; 115:168-78.

  26. Koomdee N, Pratoomwun J, Jantararoungtong T, Theeramoke V, Tassaneeyakul W, Klaewsongkram J, et al. Association of HLA-A and HLA-B alleles with lamotrigine-induced cutaneous adverse drug reactions in the thai population. Front Pharmacol. 2017;8:879




2020     |     www.medigraphic.com